Zobrazeno 1 - 8 of 8 pro vyhledávání: '"Althea House"'
1
Akademický článek
Demonstrating the capacity of the National Advisory Committee on Immunization for timely responses to post-market vaccine monitoring signals: Canada’s experience with the live-attenuated influenza vaccine
Autor: Linlu Zhao, Kelsey Young, Althea House, Rob Stirling, Matthew Tunis
Publikováno v: Canada Communicable Disease Report, Vol 47, Iss 56, Pp 279-284 (2021)
Over the last several years, the recommended use of the live-attenuated influenza vaccine (LAIV) for children has evolved in the United States (US) in response to evidence of a potential decrease in LAIV effectiveness based on post-market monitoring.
Externí odkaz: https://doaj.org/article/85a98e891ce640638bcfa8bdb76cd1cd
Zobrazit plný text záznamu
2
Akademický článek
Démontrer la capacité du Comité consultatif national de l’immunisation à réagir rapidement aux signaux de surveillance des vaccins après leur mise sur le marché : l’expérience du Canada avec le vaccin antigrippal vivant atténué
Autor: Linlu Zhao, Kelsey Young, Althea House, Rob Stirling, Matthew Tunis
Publikováno v: Canada Communicable Disease Report, Vol 47, Iss 56, Pp 306-311 (2021)
Au cours des dernières années, l’utilisation recommandée du vaccin vivant atténué contre l’influenza (VVAI) pour les enfants a évolué aux États-Unis en réponse aux preuves d’une diminution potentielle de l’efficacité du VVAI basées
Externí odkaz: https://doaj.org/article/2b506259c6994f5193e26e3aa6550940
Zobrazit plný text záznamu
3
Démontrer la capacité du Comité consultatif national de l’immunisation à réagir rapidement aux signaux de surveillance des vaccins après leur mise sur le marché : l’expérience du Canada avec le vaccin antigrippal vivant atténué
Autor: Robert G Stirling, Matthew Tunis, Kelsey Young, Linlu Zhao, Althea House
Publikováno v: Canada Communicable Disease Report, Vol 47, Iss 56, Pp 306-311 (2021)
Au cours des dernières années, l’utilisation recommandée du vaccin vivant atténué contre l’influenza (VVAI) pour les enfants a évolué aux États-Unis en réponse aux preuves d’une diminution potentielle de l’efficacité du VVAI basées
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a8105c13f6238068399cf83fee3f712
https://doi.org/10.14745/ccdr.v47i56a06f
Zobrazit plný text záznamu
4
Demonstrating the capacity of the National Advisory Committee on Immunization for timely responses to post-market vaccine monitoring signals: Canada’s experience with the live-attenuated influenza vaccine
Autor: Robert G Stirling, Althea House, Linlu Zhao, Kelsey Young, Matthew Tunis
Publikováno v: Canada Communicable Disease Report, Vol 47, Iss 56, Pp 279-284 (2021)
Can Commun Dis Rep
Over the last several years, the recommended use of the live-attenuated influenza vaccine (LAIV) for children has evolved in the United States (US) in response to evidence of a potential decrease in LAIV effectiveness based on post-market monitoring.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e1b8e90f4a237c58147e8a9d0f77e33
https://doi.org/10.14745/ccdr.v47i56a06
Zobrazit plný text záznamu
6
Overview of the respiratory syncytial virus vaccine candidate pipeline in Canada
Autor: Althea House, Wendy Vaudry, Caroline Quach, Dorothy Moore, April Killikelly, Matthew Tunis
Publikováno v: Can Commun Dis Rep
A vaccine for respiratory syncytial virus (RSV) has been actively sought for over 60 years due to the health impacts of RSV disease in infants, but currently the only available preventive measure in Canada and elsewhere is limited to passive immuniza
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e90c2d8fdba755f7ba27c3bd81a30c6c
https://doi.org/10.14745/ccdr.v46i04a01
Zobrazit plný text záznamu
8
Gap analyses to assess Canadian readiness for respiratory syncytial virus vaccines: Report from an expert retreat
Autor: Christina Bancej, Matthew Tunis, April Killikelly, Man Wah Yeung, Caroline Quach, Amanda Shane, Wendy Vaudry, Althea House, Dorothy Moore
Respiratory syncytial virus (RSV) can cause severe disease in infants and older adults. Various vaccine candidates are in development and may become authorized for use in Canada within the next 2-5 years. The Public Health Agency of Canada sought to
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cb666fb2a7c6e3a74e4389ff625bc8b
https://europepmc.org/articles/PMC7145429/
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje